G1 today reiterated its year 2023 net revenue guidance. The Company expects to generate between $50M-$60M in COSELA net revenue in 2023. G1’s product revenue guidance was initially provided in its fourth quarter and FY22 financial results and business update, and is based on expectations for continued acceleration of sales performance of COSELA in the U.S.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GTHX:
- G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
- G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
